Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIZE Global: ZS in Hyperkalemia
NCT02875834Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Started Mar 2017; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT02875834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875834.